Cord Blood CD34⁺ Hematopoietic Stem/Progenitor Cell derived Dendritic Cell (DC) Production Service

Creative Biolabs provides a cord blood CD34⁺ dendritic cell (DC) production service that enables robust and scalable generation of high-quality dendritic cells from cord blood–derived progenitors, supporting reliable modeling of human immune signaling and antigen presentation and facilitating the study of immune pathways, immunomodulatory agent screening, and vaccine development.

Introduction

Cord blood-derived CD34⁺ hematopoietic progenitors offer a potent source for generating dendritic cells ex vivo. High-performance isolation and cytokine-mediated protocols yield functional DCs suited for immunological studies, with demonstrated scalability and phenotype stability. These advances underpin our production service, ensuring both quality and reproducibility.

Service

Creative Biolabs' cord blood CD34⁺ hematopoietic stem/progenitor cell (HSPC)-derived DC production service provides a robust and scalable solution for obtaining large quantities of highly functional dendritic cells. We address the critical need for consistent, high-quality DCs in diverse research and therapeutic applications, including cancer immunotherapy, infectious disease studies, and immunogenicity testing. Our service delivers phenotypically mature and functionally potent DCs tailored to your specific project requirements, ensuring reliable performance in downstream applications. This translates to accelerated research timelines and enhanced confidence in your experimental outcomes.

• Robust Cell Isolation and Expansion: We use efficient, validated methods to isolate CD34⁺ hematopoietic stem/progenitor cells from cord blood, ensuring high purity and viability.
• Optimized Differentiation Protocols: Using proprietary two-step culture systems, we direct CD34⁺ cells to differentiate into mature, functional DC subsets. Autologous/homologous cord blood plasma enhances differentiation and DC potency while minimizing monocytic pathways.
• Comprehensive Functional Validation:
  1. Antigen Uptake Assays
  2. Chemotaxis Assays
  3. Allogeneic Mixed Leukocyte Reaction
  4. Cytokine Secretion Profiling

What We Can Offer

How to Work

Advantages

• Robust Cell Sourcing & Expansion: We ensure starting material quality assessment and provide large-scale expansion of CD34⁺ cells, yielding substantial growth of functional DC precursors.
• Scalable & Flexible Production: From research to preclinical/clinical scales, our platforms handle fresh/cryopreserved CD34⁺ cells for project flexibility.
• Tailored Solutions: Fully customized services adapt protocols, outputs, and quality control to meet specific project requirements.

Scientific Backing

Summary: Focused on identifying the molecular markers of naive CD34⁻/CD34⁺ hematopoietic stem/progenitor cell populations, this research analyzed samples from cord blood and bone marrow. Cord blood had more Lin−CD34−CD38 Low/− cells with lower aldehyde dehydrogenase, reduced clonogenicity, but potent megakaryocyte/erythrocyte differentiation. Proteomics revealed 85.6% similarity and 14.4% differential proteins; subsets exhibit distinct traits, with potential novel markers.

Fig.1 Hierarchical cluster analysis for proteins associated with CD34⁻ and CD34⁺ populations.¹

FAQs

Why Choose Us

Choosing Creative Biolabs for your cord blood CD34⁺ hematopoietic stem/progenitor cell-derived dendritic cell production service means partnering with a leader in cellular immunotherapy, committed to accelerating your scientific breakthroughs. What sets us apart is our exceptional expertise, cutting-edge technological platforms, and uncompromising dedication to quality.

Customer Reviews

"Using Creative Biolabs' cord blood CD34⁺ DC production service in our cancer vaccine research has significantly improved the efficiency of T-cell priming. The DCs generated consistently showed higher expression of co-stimulatory markers and a favorable IL-12/IL-10 ratio compared to our in-house methods, leading to more robust antigen-specific T cell responses." – Dr. A. B*er.

"We transitioned to Creative Biolabs for large-scale production of functional DCs for our preclinical studies, and their service has been exceptional. The two-step culture system consistently yields a high quantity of mature DCs, and their quality control ensures reliable functional potency, addressing our previous scalability challenges with alternative sources."–Dr. S. C*uz.

How to Contact Us

Ready to unlock the full potential of Cord Blood CD34⁺-derived Dendritic Cells for your next breakthrough? Our team of scientific experts is eager to discuss your specific project needs, provide detailed technical insights, and offer tailored solutions.

Reference

1. Gaafar, Ameera et al. "Distinct Phenotypic and Molecular Characteristics of CD34- and CD34⁺ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications." Diagnostics (Basel, Switzerland) vol. 15,4 447. 12 Feb. 2025, https://doi.org/10.3390/diagnostics15040447. Distributed under Open Access License CC BY 4.0, without modification.